Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
ALDER BIOPHARMACEUTICALS INC (ALDR) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/06/2019 8-K Quarterly results
05/02/2019 8-K Quarterly results
Docs: "Alder BioPharmaceuticals® Reports First Quarter 2019 Financial and Operating Results - FDA sets eptinezumab PDUFA date of February 21, 2020; launch expected in first quarter of 2020 - - Acute study planned for potential eptinezumab label expansion -"
02/25/2019 8-K Quarterly results
11/05/2018 8-K Quarterly results
Docs: "Alder BioPharmaceuticals® Reports Third Quarter 2018 Financial and Operating Results - Biologics License Application submission on track for Q1 2019 - - Robust manufacturing package for BLA submission to include"
05/08/2018 8-K Quarterly results
Docs: "Alder BioPharmaceuticals® Reports First Quarter 2018 Financial and Operating Results - 12-Month Data Presented at American Academy of Neurology Annual Meeting Demonstrated Eptinezumab Further Reduced Migraine Risk Following Third and Fourth Quarterly Infusions -"
11/07/2017 8-K Quarterly results
Docs: "Alder BioPharmaceuticals® Announces Third Quarter 2017 Financial and Operating Results – PROMISE 2 pivotal trial completed enrollment and top-line data on track for 1H18 –"
08/08/2017 8-K Quarterly results
Docs: "Alder BioPharmaceuticals® Announces Second Quarter 2017 Financial and Operating Results – Positive top-line PROMISE 1study results further support eptinezumab’s unique clinical profile –"
02/23/2017 8-K Form 8-K - Current report
10/27/2016 8-K Form 8-K - Current report
07/26/2016 8-K Form 8-K - Current report
04/28/2016 8-K Quarterly results
Docs: "Alder BioPharmaceuticals Reports First Quarter 2016 Financial and Operating Results - Robust Clinical Results Support Continued Advancement of Accelerated ALD403 Development Program-"
02/23/2016 8-K Quarterly results
Docs: "Alder BioPharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial and Operating Results Conference Call Today at 5 p.m. EST"
11/05/2015 8-K Quarterly results
Docs: "Alder BioPharmaceuticals Reports Third Quarter 2015 Financial and Operating Results Initiated First of Two Pivotal Clinical Trials Planned to Support BLA Filing for ALD403 in Migraine Prevention Two ALD403 Data Readouts Anticipated in 1Q16"
08/05/2015 8-K Quarterly results
Docs: "Alder BioPharmaceuticals Reports Second Quarter 2015 Financial and Operating Results"
05/07/2015 8-K Quarterly results
Docs: "Alder BioPharmaceuticals Reports First Quarter 2015 Financial and Operating Results"
03/04/2015 8-K Quarterly results
Docs: "Alder BioPharmaceuticals Reports Fourth Quarter and Year-End 2014 Financial and Operating Results - Provides Anticipated 2015 Pipeline Advancement Milestones -"
11/03/2014 8-K Quarterly results
Docs: "December 31, 2013"
08/05/2014 8-K Quarterly results
Docs: "Initiate ALD403 Phase 2b trials in migraine: Alder plans to initiate Phase 2b trials of ALD403 ) for the treatment of chronic and frequent episodic migraines in the second half of 2014 and the first half of 2015, respectively. · Complete Clazakizumab Phase 2b trial in RA: Alder’s collaboration partner, Bristol-Myers Squibb, plans to complete the primary outcome in the Phase 2b follow-on trial for Clazakizumab for the treatment of rheumatoid arthritis in the first half of 2015. · Present Phase 2 data in PsA: Alder’s collaboration partner, Bristol-Myers Squibb, plans to present data from the Phase 2 trial for Clazakizumab for the treatment of psoriatic arthritis by the end of 2014. Conference Call and Webcast Alder will host a conference call today at 5:00 p.m. EDT to discuss these second qu..."
06/18/2014 8-K Quarterly results
Docs: "Stern Investor Relations, Inc."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy